TheBigBrodie
Member
After being on Mk for the past 8 weeks my insulin resistance is on the high resulting in increased blood sugar (All according to my doctor) what methods should I use to lower this. Foods? Supplements? Etc. thanks!
After being on Mk for the past 8 weeks my insulin resistance is on the high resulting in increased blood sugar (All according to my doctor) what methods should I use to lower this. Foods? Supplements? Etc. thanks!
After being on Mk for the past 8 weeks my insulin resistance is on the high resulting in increased blood sugar (All according to my doctor) what methods should I use to lower this. Foods? Supplements? Etc. thanks!
Keto 1-2 weeks will fix you up
Just curious what is your fasted blood sugar reading and what dosage are you taking per day?
After being on Mk for the past 8 weeks my insulin resistance is on the high resulting in increased blood sugar (All according to my doctor) what methods should I use to lower this. Foods? Supplements? Etc. thanks!
Berberine 500mg/d.
20mg a day of mk and the blood sugar is 130
Are you taking any stimulants? Caffeine?
Interesting. Do stims affect blood sugar?
Generally speaking, if you're using GH or a GH secretagogue and it's causing high blood sugar then you want a long acting insulin such as lantus to take the stress off your pancreas. 'Else you get the beetus.
Generally speaking, if you're using GH or a GH secretagogue and it's causing high blood sugar then you want a long acting insulin such as lantus to take the stress off your pancreas. 'Else you get the beetus.
Berberine 500mg/d.
When would you dose the berberine hairygrandpa ?
I did it mornings. There is a product on amazon I use, with 900mg Berberine HCL. Don't go over 900mg/d, got hypo on 1800mg.
I did it mornings. There is a product on amazon I use, with 900mg Berberine HCL. Don't go over 900mg/d, got hypo on 1800mg.
Which brand I found a few
This is odd to me .... can someone explain this to me . I was under the impression mk would be lowering blood glucose and some people even experience the tingles from low blood sugar .
R. Nass, S.S. Pezzoli, M.C. Oliveri, J.T. Patrie, F.E. Harrell Jr., J.L. Clasey, S.B. Heymsfield, M.A. Bach, M.L. Vance, and M.O. Thorner. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. A Randomized Trial. 4 November 2008 issue of Annals of Internal Medicine (volume 149, pages 601-611).
Insulin Sensitivity
Appendix Figure 4 shows individual glucose and HbA1c responses. Mean fasting blood glucose levels did not change in the placebo group (0.0 mmol/L [CI, 0.3 to 0.2 mmol/L]; 1.0 mg/dL [CI, 5.0 to 3.0 mg/dL]) and increased 0.3 mmol/L (CI, 0.1 to 0.4 mmol/L; 5.0 mg/dL [CI, 2.0 to 7.0 mg/dL]; P= 0.015) in the MK-677 group. In 2 placebo recipients and 16 MK-677 recipients, fasting glucose increased from less than 5.6 mmol/L to 5.6 to 6.1 mmol/L [101 to 110 mg/dL]. In 3 MK-677 recipients with baseline fasting glucose concentrations less than 5.6 mmol/L [100 mg/dL] and 3 with concentrations greater than 5.6 mmol/L, glucose levels increased to 6.1 to 6.7 mmol/L (110 to 120 mg/dL) in 4 participants and to 6.9 mmol/L (125 and 126 mg/dL) in 2 participants. Mean HbA1c level decreased in the placebo group and increased in the MK-677 group (change, 0.1% [CI, 0.2% to 1.0%] vs. 0.2% [CI, 0.1% to 0.3%], respectively; P= 0.002); at 12 months, 8 participants had an HbA1c level greater than 6% (6.1% in 4, 6.3% in 3, and 6.4% in 1). Insulin sensitivity, as estimated by the Quicki Index, was also reduced after 12 months of treatment (P <0.001) (Appendix Table 8). One 81-year-old man had an increase in fasting blood glucose and HbA1c levels after crossing over from placebo to MK-677; after dose reduction and institution of a low-carbohydrate diet, the values returned to normal.
Discussion
Both growth hormone and MK-677 increase insulin resistance and blood glucose in elderly persons (22, 33, 41–42). We found statistically significant but small increases in fasting blood glucose and HbA1c levels at 12 months. Considering the results of short-term studies with MK-677 (9, 43),, which found no statistically significant increase in serum cortisol, the small increase in serum cortisol that we found is unlikely to underlie the increase in fasting glucose level.
9. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, . Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996; 81:4249-57. PubMed
22. Plotkin D, Ng J, Farmer M, Gelato M, Kaiser F, Kiel D, . Use of MK-677, an oral GH secretagogue, in frail elderly subjects. Endocrinol Metab. 1997; 4:Suppl A35-36.
33. Blackman MR, Sorkin JD, Mnzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, . Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002; 288:2282-92. PubMed
41. del Rincon JP, Iida K, Gaylinn BD, McCurdy CE, Leitner JW, Barbour LA, . Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 2007; 56:1638-46. PubMed
42. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, , MK-677/Alendronate Study Group. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001; 86:1116-25. PubMed
43. Svensson J, Lnn L, Jansson JO, Murphy G, Wyss D, Krupa D, . Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of Clinical Endocrinology & Metabolism. 1998; 83:362-9. PubMed
#42
Discussion
The use of GH in elderly patients is limited due to the frequent occurrence of adverse effects, such as carbohydrate intolerance or fluid retention (15, 18). Although it was anticipated that MK-677 might reduce the incidence of these adverse effects by producing a more physiological pattern of GH release, adverse effects did occur; 25 patients (8.2%) discontinued the study due to a drug-related adverse experience, including 2 patients with hypertension, 2 with fluid retention, and 3 patients who became hyperglycemic. These changes reversed after discontinuation of treatment.........The 3 patients who became hyperglycemic. These changes reversed after discontinuation of treatment.
#43
Discussion
Fasting levels of glucose and insulin were unchanged in the present study, but the OGTT demonstrated an impaired glucose homeostasis after 2 and 8 weeks of MK-677 treatment. The tendency to an improvement from 2 to 8 weeks of treatment is probably not explainable by changes in GH secretion, because the GH response to MK-677 was similar at 2 and 8 weeks of treatment. A similar pattern has been observed in a study of GH deficiency, in which an initial deterioration of insulin resistance was restored to baseline values after 6 months of GH treatment (44). Skeletal muscle is the major site of glucose disposal (45), IGF-I stimulates glucose transport into skeletal muscle in vitro (46), and GH treatment of hypophysectomized rats increases the proportion of insulin-sensitive type I muscle fibers (47). Therefore, the increase in FFM found in the present study or any related changes in muscle metabolism or morphology that may have occurred might help to explain the improvement in glucose homeostasis between 2 and 8 weeks of treatment.
Read for yourself: